Federal Tuberculosis Task Force Plan in Response to the Institute of Medicine Report, Ending Neglect: The Elimination of Tuberculosis in the United States
Return to Federal TB Task Force Plan Main Menu
The documents listed below are historical, archived information. The information contained in these documents, while accurate at the time of release, may not be the most current available.
Strategies and Action Steps
Domestic Federal Actions in Response to the Institute
of Medicine Report on TB:
Ending Neglect: The Elimination of Tuberculosis in the United States
D. Global U.S. Actions in Response to the Institute of Medicine Report on TB: Ending Neglect: The Elimination of Tuberculosis in the United States.
This brief but important section has been developed by a smaller group that includes representation from the U.S. Agency for International Development, the National Institutes of Health, and the Centers for Disease Control and Prevention.
IOM Recommendation 6.1: “To decrease the number of foreign-born individuals with tuberculosis in the United States, to minimize the spread and impact of multidrug-resistant tuberculosis, and to improve global health...”
Strategies |
Action Steps |
---|---|
1. In collaboration with the World Health Organization (WHO), develop models for diagnosis and treatment of MDR TB in countries with high MDR TB rates. Lead Agencies: CDC, USAID Collaborating Agency: NIH Start Date: FY 2002 Completion Date: Ongoing |
a) Implement and expand model directly observed treatment, short course (DOTS) programs to prevent further creation of MDR TB caused by improper treatment of new TB patients.
b) Develop and implement pilot DOTS-Plus projects to treat existing MDR TB patients and prevent MDR TB.
c) Assist in the development of "Centers of Excellence" to ensure that MDR TB is addressed, to build high- grade local capacity, and to serve as regional training centers for professionals from other countries.
d) Evaluate the cost effectiveness and appropriate use of rapid methods for diagnosis of MDR TB.
e) Conduct drug resistance surveillance to measure the extent of MDR
TB and to determine
|
2. Provide international technical and programmatic assistance aimed at reducing the impact of TB globally. Lead Agencies: CDC, USAID, NIH Start Date: FY 2002 Completion Date: Ongoing |
a) Provide technical assistance to countries for TB surveillance.
b) Provide technical assistance to improve and enhance TB laboratory capabilities.
c) Develop and promote WHO/IUATLD/CDC national external quality assessment guidelines to monitor and improve the quality of AFB microscopy.
d) Conduct operational research to improve diagnosis and treatment of HIV-associated TB.
e) Conduct large-scale feasibility and cost-effectiveness studies of various regimens for the treatment of latent TB infection in HIV-infected persons.
f) Provide technical assistance for developing and implementing institutional infection control strategies.
g) Provide onsite technical assistance to national TB control programs.
|
3. Strengthen TB research capability in high-burden countries to enhance ability to develop and test improved treatment, prevention, and control strategies. Lead Agencies: CDC, NIH, USAID Collaborating Agency: None Start Date: FY 2002 |
a) Expand and conduct training and technology transfer in high-burden countries.
b) Enhance needed infrastructure, including laboratory facilities and Internet connectivity.
c) Conduct clinical trials of novel therapeutic, diagnostic, and prevention
strategies in
|